Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 61

1.

Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche.

Tsukamoto S, Løvendorf MB, Park J, Salem KZ, Reagan MR, Manier S, Zavidij O, Rahmat M, Huynh D, Takagi S, Kawano Y, Kokubun K, Thrue CA, Nagano K, Petri A, Roccaro AM, Capelletti M, Baron R, Kauppinen S, Ghobrial IM.

Leukemia. 2018 Jun 20. doi: 10.1038/s41375-018-0161-6. [Epub ahead of print]

PMID:
29925904
2.

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.

Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, Rodon P, Van Droogenbroeck J, Qiu L, Cavo M, Van de Velde A, Lahuerta JJ, Allangba O, Lee JH, Boyle E, Perrot A, Moreau P, Manier S, Attal M, Roussel M, Mohty M, Mary JY, Civet A, Costa B, Tinel A, Gaston-Mathé Y, Facon T.

Leukemia. 2018 Jun;32(6):1404-1413. doi: 10.1038/s41375-018-0133-x. Epub 2018 Apr 26.

3.

Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.

Manier S, Park J, Capelletti M, Bustoros M, Freeman SS, Ha G, Rhoades J, Liu CJ, Huynh D, Reed SC, Gydush G, Salem KZ, Rotem D, Freymond C, Yosef A, Perilla-Glen A, Garderet L, Van Allen EM, Kumar S, Love JC, Getz G, Adalsteinsson VA, Ghobrial IM.

Nat Commun. 2018 Apr 27;9(1):1691. doi: 10.1038/s41467-018-04001-5.

4.

Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.

Kurdi AT, Glavey SV, Bezman NA, Jhatakia A, Guerriero JL, Manier S, Moschetta M, Mishima Y, Roccaro A, Detappe A, Liu CJ, Sacco A, Huynh D, Tai YT, Robbins MD, Azzi J, Ghobrial IM.

Mol Cancer Ther. 2018 Jul;17(7):1454-1463. doi: 10.1158/1535-7163.MCT-17-0998. Epub 2018 Apr 13.

PMID:
29654064
5.

Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.

Kawano Y, Zavidij O, Park J, Moschetta M, Kokubun K, Mouhieddine TH, Manier S, Mishima Y, Murakami N, Bustoros M, Pistofidis RS, Reidy M, Shen YJ, Rahmat M, Lukyanchykov P, Karreci ES, Tsukamoto S, Shi J, Takagi S, Huynh D, Sacco A, Tai YT, Chesi M, Bergsagel PL, Roccaro AM, Azzi J, Ghobrial IM.

J Clin Invest. 2018 Jun 1;128(6):2487-2499. doi: 10.1172/JCI88169. Epub 2018 May 14.

6.

Targeting MYC in multiple myeloma.

Jovanović KK, Roche-Lestienne C, Ghobrial IM, Facon T, Quesnel B, Manier S.

Leukemia. 2018 Jun;32(6):1295-1306. doi: 10.1038/s41375-018-0036-x. Epub 2018 Feb 22. Review.

PMID:
29467490
7.

Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation.

Takagi S, Tsukamoto S, Park J, Johnson KE, Kawano Y, Moschetta M, Liu CJ, Mishima Y, Kokubun K, Manier S, Salem KZ, Huynh D, Sacco A, Forward J, Roccaro AM, Battinelli EM, Ghobrial IM.

Clin Cancer Res. 2018 May 15;24(10):2430-2439. doi: 10.1158/1078-0432.CCR-17-2003. Epub 2018 Feb 9.

PMID:
29440174
8.

Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström's macroglobulinemia.

Bertrand E, Jouy N, Manier S, Fouquet G, Guidez S, Boyle E, Noel S, Tomowiak C, Herbaux C, Schraen S, Preudhomme C, Quesnel B, Poulain S, Leleu X.

Oncotarget. 2017 Dec 4;8(68):112917-112927. doi: 10.18632/oncotarget.22872. eCollection 2017 Dec 22.

9.

Different in vitro and in vivo tools for elucidating the human metabolism of alpha-cathinone-derived drugs of abuse.

Manier SK, Richter LHJ, Schäper J, Maurer HH, Meyer MR.

Drug Test Anal. 2018 Jan 4. doi: 10.1002/dta.2355. [Epub ahead of print]

PMID:
29314710
10.

[Circulating exosomal microRNA as biomarkers in mutiple myeloma].

Manier S, Leleu X, Avet-Loiseau H.

Med Sci (Paris). 2017 Nov;33(11):939-941. doi: 10.1051/medsci/20173311008. Epub 2017 Dec 4. French. No abstract available.

PMID:
29200389
11.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C.

Blood. 2018 Jan 18;131(3):301-310. doi: 10.1182/blood-2017-07-795047. Epub 2017 Nov 17.

12.

Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet-Induced Obesity in Male Mice.

Bornstein S, Moschetta M, Kawano Y, Sacco A, Huynh D, Brooks D, Manier S, Fairfield H, Falank C, Roccaro AM, Nagano K, Baron R, Bouxein M, Vary C, Ghobrial IM, Rosen CJ, Reagan MR.

Endocrinology. 2017 Oct 1;158(10):3369-3385. doi: 10.1210/en.2017-00299.

PMID:
28977604
13.

Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.

Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, Ebright RY, Shi J, Park J, Glavey SV, Devine WG, Liu CJ, Leleu X, Quesnel B, Roche-Lestienne C, Snyder JK, Brown LE, Gray N, Bradner J, Whitesell L, Porco JA Jr, Ghobrial IM.

Sci Transl Med. 2017 May 10;9(389). pii: eaal2668. doi: 10.1126/scitranslmed.aal2668.

14.

A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation.

Sacco A, Kawano Y, Moschetta M, Zavidij O, Huynh D, Reagan M, Mishima Y, Manier S, Park J, Morgan E, Takagi S, Wong KK, Carrasco R, Ghobrial IM, Roccaro AM.

Am J Hematol. 2017 Aug;92(8):E138-E145. doi: 10.1002/ajh.24778. Epub 2017 Jun 15.

PMID:
28474779
15.

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.

Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, Massoud M, Perilla-Glen A, Aljawai Y, Huynh D, Roccaro AM, Sacco A, Capelletti M, Detappe A, Alignani D, Anderson KC, Munshi NC, Prosper F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson VA, Michor F, San Miguel JF, Ghobrial IM.

Cell Rep. 2017 Apr 4;19(1):218-224. doi: 10.1016/j.celrep.2017.03.025.

16.

Proteomic characterization of human multiple myeloma bone marrow extracellular matrix.

Glavey SV, Naba A, Manier S, Clauser K, Tahri S, Park J, Reagan MR, Moschetta M, Mishima Y, Gambella M, Rocci A, Sacco A, O'Dwyer ME, Asara JM, Palumbo A, Roccaro AM, Hynes RO, Ghobrial IM.

Leukemia. 2017 Nov;31(11):2426-2434. doi: 10.1038/leu.2017.102. Epub 2017 Mar 27.

PMID:
28344315
17.

Prognostic role of circulating exosomal miRNAs in multiple myeloma.

Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A, Roccaro AM, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial IM.

Blood. 2017 Apr 27;129(17):2429-2436. doi: 10.1182/blood-2016-09-742296. Epub 2017 Feb 17.

18.

Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.

Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S.

Ann Oncol. 2017 Mar 1;28(3):468-477. doi: 10.1093/annonc/mdw619. Review.

PMID:
27998963
19.

Exosomes in Tumor Angiogenesis.

Salem KZ, Moschetta M, Sacco A, Imberti L, Rossi G, Ghobrial IM, Manier S, Roccaro AM.

Methods Mol Biol. 2016;1464:25-34.

PMID:
27858353
20.

Genomic complexity of multiple myeloma and its clinical implications.

Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM.

Nat Rev Clin Oncol. 2017 Feb;14(2):100-113. doi: 10.1038/nrclinonc.2016.122. Epub 2016 Aug 17. Review.

PMID:
27531699

Supplemental Content

Loading ...
Support Center